認知障害におけるVR瞳孔計測
AD、MCI、および抑うつ関連認知障害における課題誘発性瞳孔測定
With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 6, 12 and 18 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.
調査の概要
状態
詳細な説明
Cognitive performance typically declines with age and is usually accompanied by attention and memory deficits. While such changes can be consistent with normal ageing, they may also reflect affective disorders or early stages of neurodegenerative diseases (e.g. Alzheimer's Disease; AD). In clinical practice, neurocognitive tests are commonly used to distinguish age-appropriate change from pathological decline. As these tests quantify behavioral performance, they are better at detecting cognitive decline, once measurable deficits are manifested. However, they have limited sensitivity to subtle changes that can precede overt clinical symptoms by several years. This study evaluates a diagnostic approach based on pupil dilation measurements that may support earlier detection and longitudinal monitoring, potentially enabling earlier interventions.
Pupillometry provides a noninvasive index of pupil dynamics linked to arousal systems relevant to cognition, including the locus coeruleus-noradrenergic (LC-NA) system. LC-NA activity is coupled to pupil dilation via autonomic pathways, and this coupling has been demonstrated across animal and human studies. Given its widespread projections, the LC-NA system is implicated in psychiatric and neurological conditions through roles in arousal regulation, stress responsivity, attention, and memory. Pupillometry in Alzheimer's disease has often been examined using pupillary light reflex paradigms. However, simple light-flash measures may be less informative in early-stage impairment because pupil responses vary with cognitive state and task demands and do not provide a uniform, task-independent readout of LC-linked function. Accordingly, analyzing pupil responses during and immediately following cognitive tasks may be better suited to capturing subtle dysfunction relevant to prodromal processes, with light-reflex alterations potentially becoming more apparent once impairment is established. In prior work, the investigators observed pupil diameter increased with working-memory load during an N-back task. Most participants showed the expected increase in pupil dilation with task difficulty, whereas a subset exhibited pronounced atypical pupil responses despite only slight differences on standard neurocognitive measures. Building on these principles, this study uses a VR-based assessment to examine adults presenting with early, non-specific cognitive complaints. By systematically recording pupil dynamics during and following cognitive paradigms, the investigators aim to obtain readouts of LC-NA system function that may support differential diagnosis among conditions with overlapping clinical presentations (e.g. depression-related cognitive impairment vs. early dementia).
At each visit, participants are fitted with a VR headset by trained study personnel and complete VR-based assessments with concurrent eye tracking and behavioral performance recording. Assessments are conducted at baseline (T0) and repeated after 6 months (T1), 12 (T2) and 18 months (T3). At each visit, pupil responses and task performance are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Participants also complete routine neuropsychological testing, including the Montreal Cognitive Assessment (MoCA) and the CERAD battery comprising semantic fluency, Boston Naming Test, Mini-Mental State Examination (MMSE), word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. Additional assessments include the Bayer Activities of Daily Living scale (Bayer-ADL) and the Geriatric Depression Scale (GDS), as well as questionnaires assessing subjective cognitive impairment (FLei) and childhood adversity (CTQ). Sociodemographic data are recorded, including age, sex, education (years of schooling), and occupation. Blood is collected for routine laboratory measures and blood-based biomarker analyses (including phosphorylated tau 217), and clinical data from routine care are linked where available. In some cases, cerebrospinal fluid biomarkers from routine clinical evaluation are available and linked, including AD pathology markers (amyloid-β and tau measures).
Pupillometric and behavioral measures will be compared across cohorts and evaluated longitudinally across follow-up visits. Measures will also be related to routine neuropsychological assessment, as well as available clinical biomarkers (CSF amyloid-β and tau measures blood-based biomarkers and anatomical neuroimaging sequences). Prior observations suggest that pupil dilation scales with cognitive load and that task-evoked pupil responses can differ, even when standard neurocognitive measures show only subtle differences. The investigators hypothesize that task-evoked pupil response patterns will differ between cohorts and may be sensitive to change over time.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Eva Vidovic, MD
- 電話番号:0049 089-30622-1402
- メール:eva_vidovic@psych.mpg.de
研究連絡先のバックアップ
- 名前:Victor I. Spoormaker, PhD
- 電話番号:0049 089-30622-1402
- メール:ambulanz@psych.mpg.de
研究場所
-
-
Bavaria
-
München、Bavaria、ドイツ、80804
- 募集
- Max Planck Institute of Psychiatry
-
コンタクト:
- Eva Vidovic, MD
- 電話番号:0049 089 30622 1402
- メール:ambulanz@psych.mpg.de
-
コンタクト:
- Victor I. Spoormaker, PhD
- 電話番号:0049 089 30622 1402
- メール:ambulanz@psych.mpg.de
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adults aged 18-80 years will be recruited at the Max Planck Institute of Psychiatry (Munich, Germany) from inpatient wards and outpatient clinics. Patients have a suspected or confirmed clinical diagnosis of Alzheimer's disease, mild cognitive impairment, or depressive disorder with cognitive impairment. Routine clinical measures (neuropsychological testing and, CSF biomarkers, blood biomarkers, imaging) will be linked to study pupillometry outcomes.
説明
Inclusion Criteria:
- Written informed consent.
- Age 18-80 years.
- Ability to read and understand German.
- For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation.
Exclusion Criteria:
- Acute suicidality (e.g. BDI suicidality item > 1).
- Change of psychotropic medication within the last 4 weeks.
- Lifetime psychotic disorder (ICD-10 F20-29).
- Lack of capacity to consent.
- Lifetime bipolar disorder (ICD-10 F31).
- Acute substance abuse or harmful use of alcohol or other psychoactive substances.
- Parkinson's syndrome (ICD-10 G20).
- Multiple sclerosis (ICD-10 G35).
- Stroke within the last 12 months.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Alzheimer's Disease
Participants with complaints of cognitive deficits and a diagnosis of Alzheimer's disease (AD) supported by cerebrospinal fluid (CSF) biomarker profile, where available. |
|
Mild Cognitive Impairment without Alzheimer's Disease
Participants with complaints of cognitive deficits meeting criteria for mild cognitive impairment without evidence of Alzheimer's disease (CSF biomarkers not consistent with AD). |
|
Depressive Disorder With Cognitive Impairment
Participants with complaints of cognitive impairment and no evidence of Alzheimer's pathology; deficits most consistent with depressive disorder. |
|
Healthy Controls
Age-matched healthy volunteers. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Task-evoked pupil dilation during N-Back
時間枠:Baseline
|
Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back). |
Baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Resting-state pupil dynamics
時間枠:Baseline, 6, 12 and 18 months.
|
Mean and variability of pupil diameter during resting fixation. |
Baseline, 6, 12 and 18 months.
|
|
Reward-task pupil response
時間枠:Baseline, 6, 12 and 18 months.
|
Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during each condition (reward, control). |
Baseline, 6, 12 and 18 months.
|
|
N-back behavioral performance
時間枠:Baseline, 6, 12 and 18 months.
|
Behavioral performance during the VR N-back task, quantified as accuracy and reaction time for each load condition ( 0-, 1-, 2-back). |
Baseline, 6, 12 and 18 months.
|
|
Montreal Cognitive Assessment (MoCA)
時間枠:Baseline, 6, 12 and 18 months.
|
Global cognitive screening tool used to quantify overall cognitive impairment. Range: 0-30; higher scores indicate better cognitive performance. |
Baseline, 6, 12 and 18 months.
|
|
CERAD cognitive battery (CERAD-Plus), norm-referenced z-scores
時間枠:Baseline, 6, 12 and 18 months.
|
CERAD-Plus subtests include semantic fluency, Boston Naming Test, word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. The subtests will be evaluated using age-/education-adjusted norm-referenced z-scores. A z-score of 0 corresponds to the normative mean; higher z-scores indicate better cognitive performance and lower z-scores indicate worse performance. |
Baseline, 6, 12 and 18 months.
|
|
Bayer Activities of Daily Living (Bayer-ADL)
時間枠:Baseline, 6, 12 and 18 months.
|
Functional status measured using the Bayer-ADL mean item score (quotient). Range: 1.00-10.00. Higher scores indicate worse functional impairment (more difficulty with activities of daily living). |
Baseline, 6, 12 and 18 months.
|
|
Geriatric Depression Scale
時間枠:Baseline, 6, 12 and 18 months.
|
Geriatric Depression Scale, 30-item version (GDS-30), total score (depressive symptoms). Range: 0-30; higher scores indicate more depressive symptoms. |
Baseline, 6, 12 and 18 months.
|
|
Subjective cognitive impairment (Fragebogen zur geistigen Leistungsfähigkeit; FLei), total score
時間枠:Baseline, 6, 12 and 18 months.
|
35-item self-report assessing cognitive difficulties over the last 6 months (0-4 per item). Range: 0-140. Higher scores indicate greater subjective cognitive impairment (more perceived difficulties). |
Baseline, 6, 12 and 18 months.
|
|
Childhood Trauma Questionnaire (CTQ)
時間枠:Baseline.
|
Retrospective recall-based measures administered to adults. Used to determine experiences of childhood trauma. Higher scores indicate greater childhood adversity. |
Baseline.
|
|
Blood-based biomarkers
時間枠:Baseline, 6, 12 and 18 months.
|
Blood biomarker concentrations assessed from collected blood samples, including phosphorylated tau 217 (p-tau217) and Aβ1-42/Aβ1-40 ratio. |
Baseline, 6, 12 and 18 months.
|
|
CSF Alzheimer's disease pathology markers
時間枠:Baseline.
|
CSF biomarkers from routine clinical evaluation where available, including Aβ1-42, Aβ1-40, Aβ1-42/Aβ1-40 ratio, total tau, and phosphorylated tau. |
Baseline.
|
|
Task-evoked pupil dilation during N-Back
時間枠:Baseline, 6, 12 and 18 months.
|
Pupil response metrics (mean relative pupil diameter in each condition; load-dependent slope across conditions) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back). |
Baseline, 6, 12 and 18 months.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Between-group differences in N-back pupil metrics
時間枠:Baseline, 6, 12 and 18 months.
|
Comparison of the primary N-back pupil load metric across the four cohorts (Alzheimer's disease, mild cognitive impairment, depressive disorder with cognitive impairment, healthy controls). |
Baseline, 6, 12 and 18 months.
|
|
Association between task-evoked pupil responses and cognitive test performance
時間枠:Baseline, 6, 12 and 18 months.
|
Association between the N-back pupil metrics and cognitive performance measures (MoCA total score; CERAD-Plus subtest z-scores). |
Baseline, 6, 12 and 18 months.
|
|
Association between task-evoked pupil responses and AD pathology markers
時間枠:Baseline through 18 months, using biomarker time points available
|
Association between the N-back pupil metrics and available biomarkers of AD pathology (CSF and blood-based biomarkers). |
Baseline through 18 months, using biomarker time points available
|
|
Change from baseline in N-back pupil metrics
時間枠:Baseline, 6, 12 and 18 months.
|
Within-participant change from baseline in the prespecified N-back pupil load metric |
Baseline, 6, 12 and 18 months.
|
協力者と研究者
捜査官
- 主任研究者:Victor I. Spoormaker, PhD、Max-Planck-Institute of Psychiatry
出版物と役立つリンク
一般刊行物
- Murphy PR, O'Connell RG, O'Sullivan M, Robertson IH, Balsters JH. Pupil diameter covaries with BOLD activity in human locus coeruleus. Hum Brain Mapp. 2014 Aug;35(8):4140-54. doi: 10.1002/hbm.22466. Epub 2014 Feb 7.
- Megemont M, McBurney-Lin J, Yang H. Pupil diameter is not an accurate real-time readout of locus coeruleus activity. Elife. 2022 Feb 2;11:e70510. doi: 10.7554/eLife.70510.
- Fietz J, Pohlchen D; BeCOME Working Group; Bruckl TM, Brem AK, Padberg F, Czisch M, Samann PG, Spoormaker VI. Data-Driven Pupil Response Profiles as Transdiagnostic Readouts for the Detection of Neurocognitive Functioning in Affective and Anxiety Disorders. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Jun;9(6):580-587. doi: 10.1016/j.bpsc.2023.06.005. Epub 2023 Jun 20.
- Fietz J, Pohlchen D, Binder FP; BeCOME Working Group; Czisch M, Samann PG, Spoormaker VI. Pupillometry tracks cognitive load and salience network activity in a working memory functional magnetic resonance imaging task. Hum Brain Mapp. 2022 Feb 1;43(2):665-680. doi: 10.1002/hbm.25678. Epub 2021 Oct 8.
- Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403-50. doi: 10.1146/annurev.neuro.28.061604.135709.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 23-0991
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。